Sanofi SNY reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of \u20ac1.53 per share rose 16.8% on a reported basis and 26.7% on a constant currency rate (\u201cCER\u201d) basis, driven by cost control.<\/p>\n
Net sales rose 7.0% on a reported basis to $13.2 billion (\u20ac11.3 billion). Sales rose 13.3% on a CER basis. Sales slightly missed the Zacks Consensus Estimate of $13.4 billion.<\/p>\n
Sales rose 22.6% at CER in the United States, 8.0% in the Rest of the World (including China, Japan, Brazil and Russia) and 0.2% in Europe.<\/p>\n
All growth rates mentioned below are on a year-on-year basis and at CER.<\/p>\n
SNY\u2019s Dupixent Continues to Outperform <\/p>\n
In Immunology, blockbuster drug, Dupixent generated sales of \u20ac4.25 billion in the quarter, up 32.2% year over year, driven by strong prescription trends across all approved indications and geographies.<\/p>\n
Sales of the drug in the United States rose 35.9%. Dupixent sales rose 17.9% in Europe and 25.0% in the Rest of the World.<\/p>\n
Sanofimarkets Dupixent in partnership with Regeneron REGN. While sales are recorded by Sanofi, Regeneron records its share of profits\/losses in connection with global sales of Dupixent.<\/p>\n
SNY\u2019s Rare Disease Drugs\u2019 Performance <\/p>\n
Among Sanofi\u2019s rare disease drugs, the rare blood disorder drug, Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of \u20ac324 million in the fourth quarter, up 53.0% year over year, mainly driven by patient switches in the U.S. hemophilia A market and launch in Japan and Taiwan. As much as 85% of Altuviiio\u2019s sales were in the United States.<\/p>\n
Among the rare disease drugs in the Pompe franchise, Nexviazyme\/Nexviadzyme recorded sales of \u20ac203 million, up 15.8% year over year, mainly driven by strong sales growth in Europe. Myozyme sales declined 5.3% year over year to \u20ac122 million due to patients switching to Nexviazyme. Fabrazyme sales were \u20ac252 million, down 1.1% year over year. In the Gaucher franchise, Cerezyme sales rose 2.9% year over year to \u20ac171 million.<\/p>\n
Cablivi recorded sales of \u20ac69 million, up 1.4% year over year, driven by patient growth in the United States and Europe.<\/p>\n
Among the rare blood disorder drugs, Eloctate sales declined 16.0% to \u20ac63 million in the quarter due to patients switching to the new drug Altuviiio.<\/p>\n
Xenpozyme recorded sales of \u20ac61 million in the quarter, up 65.8% year over year.<\/p>\n
New drug Qfitlia (fitusiran), which was approved by the FDA last year in March for treating hemophilia A and B, generated \u20ac4 million in sales, the same as in the previous quarter.<\/p>\n
Story Continues <\/p>\n
Wayrilz (rilzabrutinib), which was approved for treating immune thrombocytopenia in the United States in August last year, generated \u20ac6 million in sales in the fourth quarter versus \u20ac1 million in the previous quarter.<\/p>\n
All sales of Qfitlia and Wayrilz were in the United States in the fourth quarter, as the drugs are not yet approved in ex-U.S. markets.<\/p>\n
Ayvakit, added from last year\u2019s acquisition of Blueprint Medicines, recorded sales of \u20ac168 million compared with \u20ac137 million in the previous quarter, driven by continued patient growth.<\/p>\n
SNY\u2019s Neurology, Oncology & Other Drugs <\/p>\n
In neurology medicines, Aubagio sales declined 30.8% year over year to \u20ac51 million due to the loss of exclusivity in 2023.<\/p>\n
In Oncology, Sarclisa sales rose 27.7% year over year to \u20ac157 million, driven by market share gains globally and increased use in earlier lines of treatment.<\/p>\n
In Others, Toujeo recorded sales of \u20ac332.0 million, up 18.6% year over year, driven mainly by higher sales in Rest of World. Lantus sales rose 1.1% to \u20ac419 million. Rezurock recorded sales of \u20ac113 million, down 6.1% year over year. Tzield sales were \u20ac16 million in the quarter, flat year over year.<\/p>\n
Plavix sales rose 7.6% to \u20ac214 million. Lovenox sales decreased 21.6% to \u20ac179 million.<\/p>\n
SNY\u2019s Vaccine Sales Decline <\/p>\n
Total vaccine sales declined 2.5% to \u20ac2.04 billion, mainly due to lower sales of Sanofi and partner AstraZeneca\u2019s AZN respiratory syncytial virus or RSV antibody, Beyfortusand Polio\/Pertussis\/Hib (PPH) vaccines.<\/p>\n
Sales of flu vaccines rose 31.5% year over year to \u20ac575 million due to a higher vaccination rate than expected previously. Sales of PPH vaccines declined 9.5% year over year to \u20ac551 million. Sales of meningitis, travel and other endemic vaccines declined 4.8% year over year to \u20ac227 million in the quarter.<\/p>\n
AstraZeneca-partnered Beyfortus recorded sales of \u20ac686 million in the quarter, down 14.9% year over yeardue to a tough comparison from inventory increase in the year-ago quarter.<\/p>\n
SNY Issues 2026 Guidance <\/p>\n
Sanofi issued its financial outlook for 2026.<\/p>\n
Sanofi expects sales to rise by a high single-digit percentage at CER. Sanofi expects earnings to grow faster than sales in 2026 at CER (before stock buyback). Overall, Sanofi expects to be able to sustain its profitable growth momentum in 2026.<\/p>\n
In 2026, Sanofi expects to buy back stock worth \u20ac1 billion in 2026.<\/p>\n
Our Take on SNY\u2019s Q4 Results <\/p>\n
Sanofi\u2019s fourth-quarter results were mixed as it beat estimates for earnings but missed the same for sales. Higher sales of Dupixent and contributions from new products like Altuviiio and Ayvakit drove top-line growth, offsetting lower sales of vaccines. However, influenza vaccines performed better than expected in the fourth quarter. Dupixent continues to be the key top-line driver with global sales rising above \u20ac4 billion for the second consecutive quarter. Sales of its newly launched drugs and vaccines rose almost 50% in the quarter. Sanofi\u2019s 2026 outlook was decent, and the company said it expects continued profitable growth for the next five years.<\/p>\n
Sanofi\u2019s shares were up around 1% in pre-market trading in response. Sanofi\u2019s stock has declined 15.6% in the past year against the industry\u2019s increase of 18.0%.<\/p>\n
Zacks Investment Research <\/p>\n
Image Source: Zacks Investment Research<\/p>\n
Sanofi is seeing a good uptake of its new medicines and vaccines. Altuviiio achieved blockbuster sales in 2025 and Ayvakit is expected to become the next blockbuster drug in 2026. Last year, Sanofi launched Qfitlia and Wayrilz. Some potential blockbuster assets in phase III development or under registration are amlitelimab, frexalimab and tolebrutinib. However, in December, the FDA issued a complete response letter to its new drug application, seeking approval for its BTK inhibitor, tolebrutinib, for treating non-relapsing secondary progressive multiple sclerosis. Regulatory applications for amlitelimab and frexalimab are planned in 2026 and 2027, respectively.<\/p>\n
Sanofi has also been active on the M&A front. In December, it announced a definitive agreement to acquire vaccine maker, Dynavax Technologies DVAX for $15.50 per share in cash for a total equity value of approximately $2.2 billion. The acquisition will boost Sanofi\u2019s adult vaccines franchise\u00a0by adding DVAX\u2019s marketed adult hepatitis B vaccine, Heplisav-B and a mid-stage shingles candidate. Last year, it acquired Blueprint Medicines, which has expanded its presence in rare immunological diseases and Vigil Neuroscience, which expanded its early-stage pipeline in neurology.<\/p>\n
SNY\u2019s Zacks Rank <\/p>\n
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here.<\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a><\/p>\n Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report<\/a><\/p>\n Sanofi (SNY) : Free Stock Analysis Report<\/a><\/p>\n AstraZeneca PLC (AZN) : Free Stock Analysis Report<\/a><\/p>\n Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report<\/a><\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n